Trial Profile
A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary) ; Chlorambucil; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms GLOW
- Sponsors Janssen Research & Development; Janssen-Cilag
- 12 Dec 2023 Results of updated analysis including subgroup analyses by IGHV and MRD presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing the impact of targeted agents in fully mitigating the detrimental effects of CLL on overall survival by comparing the 5-year OS of treatment-naive CLL pts in phase 3 clinical trials with the 5-year OS of age- and gender-matched general population (AGMGP) in Italy and the US (RESONATE2, ILLUMINATE, ALLIANCE, ELEVATE-TN, CLL14, GLOW, ECOG1912, FLAIR, and CLL13) were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 11 Dec 2023 According to a Janssen media release, new long-term follow-up data from this trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.